Current Situation of Health Care in Women With HBV or HCV Infection

Launched by RUIJIN HOSPITAL · Aug 29, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the health care experiences of women and men who have Hepatitis B (HBV) or Hepatitis C (HCV) infections. The study will gather information from two groups: one group of 2,000 people with HBV and another group of 500 people with HCV. For those with HBV, researchers will study patients who have had the virus for over six months and have either never been treated or stopped treatment for at least a year. For the HCV group, they will focus on individuals who have tested positive for the virus and are also treatment-naïve or have previously been treated but did not achieve a successful response.

Participants in this study will help researchers understand how long it takes to get treatment after diagnosis, how many people receive treatment, and how well the treatments work. This research is important for improving health care for those with HBV and HCV. If you are 18 years or older and fit the criteria, you might be eligible to participate. However, individuals with other serious health conditions or certain past treatment issues will not be included in the study. The trial has not started recruiting participants yet, so there will be more information available as it progresses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • HBV Cohort -
• • ≥18 years old
• • serum HBsAg positive for \>6 months
• • Treatment naïve or,
• • Patients who had been previously treated for HBV but discontinued for at least 1 year before enrollment
• • HCV Cohort -
• • ≥18 years old
• • HCV-Ab positive
• • HCV RNA positive
• • Treatment naïve or,
• • Patients who had been previously treated for HCV with a regimen containing interferon and not had a sustained virologic response.
• Exclusion Criteria:
• • HBV/HCV Co-infection
• • HIV
• • History of hepatic decompensation or hepatocellular carcinoma
• • Other carcinoma
• • Other severe liver disease
• • Severe Comorbidity like cardiovascular disease, diabetes etc.
• • Patients who had discontinued previous HCV treatment because of an adverse event.
• • Patients who had previously received any nucleotide analogue HCV NS5B inhibitor or any NS5A inhibitor
• • Patients who had discontinued previous HBV treatment because of an adverse event.